Global Bovine Respiratory Disease Treatment Market Growth (Status and Outlook) 2023-2029

Global Bovine Respiratory Disease Treatment Market Growth (Status and Outlook) 2023-2029

Bovine respiratory disease (BRD) is a multifactorial and complex disorder caused due to combination of more than one microbial pathogens, impaired host immunity, inadequate housing conditions, and environmental factors. The major factor leading to bovine respiratory diseases are host factors, environmental factors, and direct influence of infectious agents such as virus, bacteria, and parasites. However, due to increasing consumption of milk and beef products, the need for bovine respiratory disease treatment has increased across the globe.

LPI (LP Information)' newest research report, the “Bovine Respiratory Disease Treatment Industry Forecast” looks at past sales and reviews total world Bovine Respiratory Disease Treatment sales in 2022, providing a comprehensive analysis by region and market sector of projected Bovine Respiratory Disease Treatment sales for 2023 through 2029. With Bovine Respiratory Disease Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Bovine Respiratory Disease Treatment industry.

This Insight Report provides a comprehensive analysis of the global Bovine Respiratory Disease Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Bovine Respiratory Disease Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Bovine Respiratory Disease Treatment market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Bovine Respiratory Disease Treatment and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Bovine Respiratory Disease Treatment.

The global Bovine Respiratory Disease Treatment market size is projected to grow from US$ 30 million in 2022 to US$ 100.8 million in 2029; it is expected to grow at a CAGR of 18.8% from 2023 to 2029.

One of the major factors responsible for the market's growth is the increasing interests of several vendors on the development of novel drugs to gain a competitive advantage over their competitors. For instance, Bayer HealthCare launched Zelnate in the US, which is a bacterial-produced plasmid DNA including a liposome carrier that helps to stimulate the innate immune system in cattle. Furthermore, under traditional antibiotics segment also, vendors are launching various drugs such as draxxin for the cattle respiratory disease treatment. The growing focus on the development of combination drugs will drive the growth prospects for the global BRD treatment market for the next few years. Some of the major factors responsible for the growing number of development of combination drugs is the need to offer improved efficacy and ensure better treatment outcomes.

This report presents a comprehensive overview, market shares, and growth opportunities of Bovine Respiratory Disease Treatment market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Vaccines
Antibiotics
Immunomodulators
Others

Segmentation by application
Veterinary Clinics
Veterinary Hospitals
Veterinary Research Institutes
Private Veterinary Pharmacies

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Bayer HealthCare
Boehringer Ingelheim
Elanco
Merck
Zoetis
Ceva
Inovio Pharmaceuticals
Norbrook Laboratories
Plumbline Life Sciences

Please note: The report will take approximately 2 business days to prepare and deliver.